Synthesis, properties and applications of papillomavirus-like particles
Related Experiment Video
Updated: Nov 3, 2026

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay
Published on: February 10, 2022
M Sapp1, C Volpers, R E Streeck
1Institute for Medical Microbiology and Hygiene, University of Mainz, Germany.
Abstract:
Papillomavirus-like particles can be obtained by expression of the major capsid protein L1 alone or by coexpression with the minor capsid protein L2 in various systems. Virus-like particles (VPLs) and virions have very similar capsid structures. Immunization with VLPs yields antibodies neutralizing virions in vitro. Vaccination of animals with VLPs has been shown to protect against viral challenge. VLPs of human papillomavirus (HPV) are therefore the most promising vaccine candidate to prevent infections with HPVs associated with cervical cancer, the most frequent carcinoma in women worldwide.
Related Concept Videos
Subviral Agents
Size and Structure of Viral Genomes
Viral Structure
Introduction to Virus
Inhibitors of Virion Maturation and Assembly
Retrovirus Life Cycles

